Welcome to our dedicated page for IceCure Medical Ltd. Ordinary Shares news (Ticker: $ICCM), a resource for investors and traders seeking the latest updates and insights on IceCure Medical Ltd. Ordinary Shares stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect IceCure Medical Ltd. Ordinary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of IceCure Medical Ltd. Ordinary Shares's position in the market.
Rhea-AI Summary
IceCure Medical Ltd. announces groundbreaking results from an independent study on breast cancer treatment using its ProSense® System, reporting a median tumor reduction of 100% at 6 and 12 months post-cryoablation. The study conducted on inoperable women aged 60-92 showcases the effectiveness of cryoablation technology in destroying tumors non-invasively, offering new hope for patients who cannot undergo surgery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
-
Rhea-AI Summary
IceCure Medical Ltd. (Nasdaq: ICCM) announces educational events featuring ProSense® cryoablation technology at upcoming medical conferences in Japan. Dr. Fukuma to lead sessions focusing on nonsurgical tumor ablation with clinical data and pathology analysis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
IceCure Medical Ltd. (NASDAQ: ICCM) announced that the FDA has responded affirmatively to the company's request for supervisory review regarding the FDA's prior denial of IceCure's De Novo Classification Request for treating patients with early-stage, low-risk breast cancer. IceCure plans to expedite data monitoring and analysis to submit the final 5-year dataset to the FDA by April 2024, several months ahead of the Company's prior submission timeline. The ICE3 study will provide 5-year recurrence outcomes on a patient population which represents approximately 65,000 people in the U.S. alone annually. IceCure was invited by the FDA to submit real-world data from the use of ProSense® globally, including post-market commercial use in territories where ProSense® is approved for breast cancer, as well as data from independent third-party studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.25%
Tags
Rhea-AI Summary
IceCure Medical Ltd. (NASDAQ: ICCM) showcased its ProSense® System at the SIO 2024 Annual Meeting in California, receiving positive feedback from interventional oncologists. ICE3 trial data was central to the Breast Cryoablation Master Class, demonstrating a 96.91% recurrence-free rate. The Company's CEO, Eyal Shamir, expressed optimism about the adoption of cryoablation as a desirable option for early-stage breast cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.99%
Tags
-
Rhea-AI Summary
ProSense® Users Presenting Groundbreaking Research at Industry Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
-
Rhea-AI Summary
IceCure Medical Ltd. (Nasdaq: ICCM) has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Stock Market LLC. The company's ProSense® System, a cryoablation technology, has been successful in maintaining a minimum bid price of $1.00 per share for 10 consecutive business days, resolving the prior bid price deficiency matter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
IceCure Medical Ltd. (Nasdaq: ICCM) experienced a 25% increase in U.S. sales of the ProSense® system and disposable probe in 2023 compared to the previous year. The ICE3 study is nearing completion, with final data readout expected soon. The company saw significant growth in the global rollout of ProSense®, with regulatory clearances in large markets like Brazil, Canada, and China. The trend towards cryoablation procedures is on the rise, especially among breast surgeons and radiologists, with growing support from peer-reviewed journals. IceCure remains optimistic about its global expansion and distribution footprint.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.82%
Tags
-
Rhea-AI Summary
IceCure Medical Ltd. (Nasdaq: ICCM) announced the publication of a study demonstrating the potential anti-cancer benefits of its ProSense® System, a minimally-invasive cryoablation technology. The study conducted at Case Western Reserve University School of Medicine shows that cryoablation using ProSense® can activate the body's natural immune response by enhancing CD8+ T cells, potentially leading to a more robust immune response against abnormal cells. This development opens up possibilities for increased therapeutic benefits of cryoablation against solid tumors beyond tumor destruction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.76%
Tags
-
Rhea-AI Summary
IceCure Medical Ltd. (Nasdaq: ICCM) announced the publication of an independent study in the Annals of Surgical Oncology, stating that cryoablation is an oncologically safe and feasible minimally invasive procedure option for patients with early-stage, low-risk breast cancer. The study suggests that cryoablation is a superior alternative to surgical resection in terms of financial implications. The study was conducted at the Breast Center of Excellence and the Department of Surgery, School of Medicine at Texas Tech University Health Sciences Center.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.52%
Tags
Rhea-AI Summary
IceCure Medical Ltd. (NASDAQ: ICCM) has received approval from the Central Drugs Standard Control Organization in India for its ProSense® System, a minimally-invasive cryoablation technology for destroying tumors. The system is already marketed and sold in India, with the first breast cancer cryoablation procedure conducted in June 2023. IceCure aims to capitalize on the potential for significant market growth in India and maintain regulatory approvals worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.34%
Tags
IceCure Medical Ltd. Ordinary Shares
Nasdaq:ICCM
ICCM Rankings
ICCM Stock Data
55.33M
18.90M
59.3%
0.66%
0.77%
Surgical and Medical Instrument Manufacturing
Manufacturing
United States of America
Caesarea